Almac Launch XCEL™ Array - the Optimum Platform for Biomarker Discovery
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Almac has announced the launch of XCEL™ array, a biomarker discovery platform that enables the identification of biomarkers within multiple disease areas.
Almac’s propriety XCEL™ array contains 92,000 transcripts, more than is available on any other platform and the technology is optimized for use with Formalin Fixed Paraffin Embedded (FFPE) tissue, the company said.
XCEL™ array is a high density transcriptome based microarray based on the industry standard Affymetrix GeneChip® platform. The content of XCEL has been derived from high quality proprietary sequence data, as well as mining public gene expression and sequence databases. The design methodologies of the array are derived from validated methods derived for Almac’s range of cancer DSA® (Disease Specific Arrays).
The substantial content on Almac’s XCEL™ array ensures that the platform technology is suited for research in cross-disease areas, a notable advantage to pharmaceutical companies.
President and Managing Director of Almac Diagnostics, Professor Paul Harkin commented: “Our XCEL™ array provides an ideal platform for the discovery of biomarkers in a range of diseases and where cross disease compatibility is important. This array becomes an important part of our solutions for the delivery of personalized medicine.”
The XCEL™ array adds to Almac’s portfolio of proprietary discovery arrays which include; Breast DSA®, Colorectal DSA®, Lung Cancer DSA®, Ovarian Cancer DSA® and Prostate Cancer DSA®.
Almac’s propriety XCEL™ array contains 92,000 transcripts, more than is available on any other platform and the technology is optimized for use with Formalin Fixed Paraffin Embedded (FFPE) tissue, the company said.
XCEL™ array is a high density transcriptome based microarray based on the industry standard Affymetrix GeneChip® platform. The content of XCEL has been derived from high quality proprietary sequence data, as well as mining public gene expression and sequence databases. The design methodologies of the array are derived from validated methods derived for Almac’s range of cancer DSA® (Disease Specific Arrays).
The substantial content on Almac’s XCEL™ array ensures that the platform technology is suited for research in cross-disease areas, a notable advantage to pharmaceutical companies.
President and Managing Director of Almac Diagnostics, Professor Paul Harkin commented: “Our XCEL™ array provides an ideal platform for the discovery of biomarkers in a range of diseases and where cross disease compatibility is important. This array becomes an important part of our solutions for the delivery of personalized medicine.”
The XCEL™ array adds to Almac’s portfolio of proprietary discovery arrays which include; Breast DSA®, Colorectal DSA®, Lung Cancer DSA®, Ovarian Cancer DSA® and Prostate Cancer DSA®.
